The action of SGLT2 inhibitors is glucose-dependent, becoming negligible when plasma glucose concentration drops below 90/mg/dL, so the risk of hypoglycemia is lower than with insulin-dependent antidiabetic drugs [18]. This evidence concerns the gene INS and Hypoglycemia.